The Current Status of Adjuvant Chemotherapy for Colorectal Cancer in Japan: A Paradigm Shift from Oral Fluoropyridine Single Therapy to the Oxaliplatin Regimen

被引：0
作者：
Teranishi, Nobuhisa [1 ]
Uetake, Hiroyuki [1 ]
机构：
[1] Natl Hosp Org NHO, Disaster Med Ctr, Dept Clin Res, 3256 Midori Cho, Tachikawa 1900014, Japan
来源：
CANCERS | 2025年 / 17卷 / 03期
关键词：
colorectal cancer; adjuvant therapy in Japan; L-OHP; 5-FU + leucovorin; ACHIEVE trial; III COLON-CANCER; STAGE-II; SURVIVAL; FLUOROURACIL; LEUCOVORIN; TRIAL; S-1;
D O I：
10.3390/cancers17030518
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
The effectiveness of oxaliplatin (L-OHP) has been reported overseas; however, in Japan, the prognosis of colorectal cancer (CRC) patients is reported to be good, and there has been a long debate about the applicability of L-OHP combination therapy in Japan. In recent years, the results of the ACHIEVE trial have become clear, and the standard consensus in Japan establishes L-OHP combination therapy for a duration of 3 months as the adjuvant treatment for CRC.
引用
收藏
页数：5
相关论文
共 32 条
  • [21] KRAS mutational status affects oxaliplatin-based chemotherapy independently from basal mRNA ERCC-1 expression in metastatic colorectal cancer patients
    Basso, M.
    Strippoli, A.
    Orlandi, A.
    Martini, M.
    Calegari, M. A.
    Schinzari, G.
    Di Salvatore, M.
    Cenci, T.
    Cassano, A.
    Larocca, L. M.
    Barone, C.
    BRITISH JOURNAL OF CANCER, 2013, 108 (01) : 115 - 120
  • [22] Significance of postoperative adjuvant chemotherapy with an oxaliplatin-based regimen after simultaneous curative resection for colorectal cancer and synchronous colorectal liver metastasis: a propensity score matching analysis (vol 21, 188, 2021)
    Sugimoto, Kiichi
    Sakamoto, Kazuhiro
    Ii, Yuki
    Amemiya, Kota
    Sugo, Hiroyuki
    Ito, Tomoaki
    Munakata, Shinya
    Takahashi, Makoto
    Kojima, Yutaka
    Tomiki, Yuichi
    Sato, Koichi
    Saiura, Akio
    Kawasaki, Seiji
    BMC SURGERY, 2021, 21 (01)
  • [23] Using oral tegafur/uracil (UFT) plus leucovorin as adjuvant chemotherapy in stage II colorectal cancer: a propensity score matching study from Taiwan
    Yu, Yen-Lin
    Tseng, Wen-Ko
    Liao, Chun-Kai
    Yeh, Chien-Yuh
    Chen, Hong-Hwa
    Liu, Yu-Hsuan
    Liaw, Yu-Wei
    Fan, Chung-Wei
    BMC CANCER, 2023, 23 (01)
  • [24] Hepatic Arterial Infusion Chemotherapy Using Fluorouracil Followed by Systemic Therapy Using Oxaliplatin Plus Fluorouracil and Leucovorin for Patients with Unresectable Liver Metastases from Colorectal Cancer
    Hiroshi Seki
    Toshirou Ozaki
    Makoto Shiina
    CardioVascular and Interventional Radiology, 2009, 32 : 679 - 686
  • [25] Hepatic Arterial Infusion Chemotherapy Using Fluorouracil Followed by Systemic Therapy Using Oxaliplatin Plus Fluorouracil and Leucovorin for Patients with Unresectable Liver Metastases from Colorectal Cancer
    Seki, Hiroshi
    Ozaki, Toshirou
    Shiina, Makoto
    CARDIOVASCULAR AND INTERVENTIONAL RADIOLOGY, 2009, 32 (04) : 679 - 686
  • [26] Efficacy of Adjuvant Combination Therapy With Trastuzumab and Chemotherapy in HER2-positive Early Breast Cancer: A Single Institutional Cohort Study from Clinical Practice
    Okamoto, Masahiro
    Tajiri, Wakako
    Ueo, Hiroki
    Masuda, Takanobu
    Ijichi, Hideki
    Koga, Chinami
    Nakamura, Yoshiaki
    Taguchi, Kenichi
    Ohno, Shinji
    Tokunaga, Eriko
    ANTICANCER RESEARCH, 2020, 40 (06) : 3315 - 3323
  • [27] The IDEA (International Duration Evaluation of Adjuvant Chemotherapy) Collaboration: Prospective Combined Analysis of Phase III Trials Investigating Duration of Adjuvant Therapy with the FOLFOX (FOLFOX4 or Modified FOLFOX6) or XELOX (3 versus 6 months) Regimen for Patients with Stage III Colon Cancer: Trial Design and Current Status
    Andre, Thierry
    Iveson, Timothy
    Labianca, Roberto
    Meyerhardt, Jeffrey A.
    Souglakos, Ioannis
    Yoshino, Takayuki
    Paul, James
    Sobrero, Alberto
    Taieb, Julien
    Shields, Anthony F.
    Ohtsu, Atsushi
    Grothey, Axel
    Sargent, Daniel J.
    CURRENT COLORECTAL CANCER REPORTS, 2013, 9 (03) : 261 - 269
  • [28] Impact of primary tumour location and RAS/BRAF mutational status in metastatic colorectal cancer treated with first-line regimens containing oxaliplatin and bevacizumab: Prognostic factors from the AIO KRK0207 first-line and maintenance therapy trial
    Hegewisch-Becker, Susanna
    Noepel-Duennebacke, Stefanie
    Hinke, Axel
    Graeven, Ullrich
    Reinacher-Schick, Anke
    Hertel, Jan
    Lerchenmueller, Christian A.
    Killing, Birgitta
    Depenbusch, Reinhard
    Al-Batran, Salah-Eddin
    Lange, Thoralf
    Dietrich, Georg
    Tannapfel, Andrea
    Arnold, Dirk
    EUROPEAN JOURNAL OF CANCER, 2018, 101 : 105 - 113
  • [29] Analysis of PTEN, BRAF and PI3K status for determination of benefit from cetuximab therapy in metastatic colorectal cancer patients refractory to chemotherapy with wild-type KRAS
    Tural, Deniz
    Batur, Sebnem
    Erdamar, Sibel
    Akar, Emre
    Kepil, Nuray
    Mandel, Nil Molinas
    Serdengecti, Suheyla
    TUMOR BIOLOGY, 2014, 35 (02) : 1041 - 1049
  • [30] Study protocol of a single-arm phase 2 study evaluating the preventive effect of topical hydrocortisone for capecitabine-induced hand-foot syndrome in colorectal cancer patients receiving adjuvant chemotherapy with capecitabine plus oxaliplatin (T-CRACC study)
    Iimura, Yohei
    Furukawa, Naoki
    Ishibashi, Masaaki
    Ahiko, Yuka
    Tanabe, Taro
    Aikou, Susumu
    Shida, Dai
    Nojima, Masanori
    Kuroda, Seiichiro
    Boku, Narikazu
    BMC GASTROENTEROLOGY, 2022, 22 (01)
1234